Ying Di

Ying Di

Auto-generated profile, based on publicly available information

Ying Di

College of Sciences, Northeastern University, Shenyang, 110819, China

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
27 July 2022 in Journal of Thrombosis and Haemostasis
Verified
Journal Article
Open access
NJNatalie Jooss
Natalie Jooss
CSChristopher W. Smith
Christopher W. Smith
ASAlexandre Slater
Alexandre Slater
SMSamantha Montague
Samantha Montague
YDYing Di
Ying Di
NPNatalie S Poulter
Natalie S Poulter
The collagen receptor glycoprotein VI (GPVI) is an attractive antiplatelet target due to its critical role in thrombosis but minor involvement in hemostasis. To investigate GPVI receptor involvement in platelet activation by collagen‐I and atherosclerotic plaque using novel blocking and non‐blocking anti‐GPVI nanobodies (Nbs). Nb effects on GPVI‐mediated signaling and function were assessed by western blot and whole blood thrombus formation under flow. GPVI clustering was visualized in thrombi using fluorescently labeled Nb28. Under arterial shear, inhibitory Nb2 blocks thrombus formation and platelet activation on collagen and plaque, but only reduces adhesion on plaque. In contrast, adhesion on collagen, but not plaque, is decreased by blocking integrin α2β1. Adhesion on plaque is maintained despite inhibition of integrins αvβ3, α5β1, α6β1, and αIIbβ3. Only combined αIIbβ3 and α2β1 blockade inhibits adhesion and thrombus formation to the same extent as Nb2 alone. Nb2 prevents GPVI signaling, with loss of Syk, Lat, and PLCɣ2 phosphorylation, especially to plaque stimulation. Non‐blocking fluorescently labeled Nb28 reveals distinct GPVI distribution patterns on collagen and plaque, with GPVI clustering clearly apparent on collagen fibers and less frequent on plaque. Clustering on collagen fibers is lost in the presence of Nb2. This work emphasizes the critical difference in GPVI‐mediated platelet activation by plaque and collagen; it highlights the importance of GPVI clustering for downstream signaling and thrombus formation. Labeled Nb28 is a novel tool for providing mechanistic insight into this process and the data suggest Nb2 warrants further investigation as a potential anti‐thrombotic agent.

2 May 2023 in Applied Mathematics and Computation
Verified
Journal Article
Closed access
YDYing Di
Ying Di
Jin-Xi ZhangJin-Xi Zhang
Jin-Xi Zhang
xuefeng zhangxuefeng zhang
xuefeng zhang

17 March 2023 in Blood Advances
Verified
Journal Article
Open access
PDF file
HBHelena C. Brown
Helena C. Brown
SBSarah Beck
Sarah Beck
SNStefano Navarro
Stefano Navarro
YDYing Di
Ying Di
EJEva Maria Soriano Jerez
Eva Maria Soriano Jerez
DSDavid Stegner
David Stegner

3 October 2021 in bioRxiv
Verified
Preprint
Open access
PDF file
HBHelena C Brown
Helena C Brown
SBSarah Beck
Sarah Beck
SNStefano Navarro
Stefano Navarro
YDYing Di
Ying Di
EJEva Maria Soriano Jerez
Eva Maria Soriano Jerez
DSDavid Stegner
David Stegner
Platelet C-type lectin-like receptor 2 (CLEC-2) has been proposed as a potential anti-thrombotic target as genetic or antibody-mediated receptor deficiency prevents occlusive thrombus formation in mice. This occurs through interaction with an unknown ligand as the endogenous ligand podoplanin is not present in the vasculature. However, the CLEC-2-podoplanin interaction does have an important role in tumour metastasis. There are currently no methods to test potential human therapeutics targeting CLEC-2, such as antibodies, in vivo . We have therefore generated and characterised a humanised CLEC-2 mouse (hCLEC-2 KI ) and developed a novel monoclonal anti-human CLEC-2 antibody, HEL1, for in vivo testing. hCLEC-2 KI mice were phenotypically normal and had comparable platelet glycoprotein receptor expression, activation and aggregation to wildtype platelets. hCLEC-2 KI mice had both comparable bleeding and vessel occlusion times to WT mice. Challenging hCLEC-2 KI mice with HEL1 or a second monoclonal anti-hCLEC-2 antibody, AYP1, resulted in transient thrombocytopenia as well as CLEC-2 depletion for more than 2 weeks but had no effect on haemostasis. This illustrates the power of the humanised CLEC-2 mouse model in evaluating novel therapeutics in vivo , including antibodies that target CLEC-2, as well as the limited effect on haemostasis when targeting CLEC-2.